Metabolic Liver Disease and Cancer Transition: Central Role of the FBP1 Regulatory Axis

Zhengtao Liu; Jun Xu; Shusen Zheng

doi:10.1002/mco2.70347

MedComm ›› 2025, Vol. 6 ›› Issue (8) : e70347 DOI: 10.1002/mco2.70347

HIGHLIGHT

Metabolic Liver Disease and Cancer Transition: Central Role of the FBP1 Regulatory Axis

Zhengtao Liu ¹^,²
, Jun Xu ²^,³
, Shusen Zheng ¹^,²^,³

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhengtao Liu, Jun Xu, Shusen Zheng. Metabolic Liver Disease and Cancer Transition: Central Role of the FBP1 Regulatory Axis. MedComm, 2025, 6(8): e70347 DOI:10.1002/mco2.70347

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	L. Gu, Y. Zhu, S. P. Nandi, et al., “FBP1 controls Liver Cancer Evolution From Senescent MASH Hepatocytes,” Nature 637, no. 8045 (2025): 461-469.

[2]	X. Wang, L. Zhang, and B. Dong, “Molecular Mechanisms in MASLD/MASH Related HCC,” Hepatology (2024): 10.1097.

[3]	M. Karin and J. Y. Kim, “MASH as an Emerging Cause of Hepatocellular Carcinoma: Current Knowledge and Future Perspectives,” Molecular Oncology 19, no. 2 (2025): 275-294.

[4]	W. Wang, K. Xu, M. Shang, et al., “The Biological Mechanism and Emerging Therapeutic Interventions of Liver Aging,” International Journal of Biological Sciences 20, no. 1 (2024): 280.

[5]	D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 12, no. 1 (2022): 31-46.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.